| 1 |
31615346 | How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature. | 2020 Jun |
1 |
| 2 |
31690489 | Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma. | 2020 Jan |
1 |
| 3 |
31706006 | Keratinocytes apoptosis contributes to crizotinib induced-erythroderma. | 2020 Feb 1 |
1 |
| 4 |
31712133 | ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials. | 2020 Apr |
3 |
| 5 |
31721468 | The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib. | 2020 Feb |
3 |
| 6 |
31756496 | Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. | 2020 Mar |
3 |
| 7 |
31766077 | Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report. | 2020 Jan |
1 |
| 8 |
31820329 | Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer. | 2020 Feb |
2 |
| 9 |
31894386 | Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes. | 2020 Apr |
2 |
| 10 |
31906956 | Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report. | 2020 Jan 6 |
4 |
| 11 |
31924369 | Transformation of EML4-ALK fusion-positive adenocarcinoma into squamous cell carcinoma in association with acquired resistance to crizotinib. | 2020 Feb |
1 |
| 12 |
31958984 | Crizotinib versus chemotherapy: a real-world cost-effectiveness study in China. | 2020 Jan |
4 |
| 13 |
31961053 | Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms. | 2020 Mar |
1 |
| 14 |
31971859 | Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer. | 2020 Apr |
1 |
| 15 |
32021525 | Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases. | 2020 |
1 |
| 16 |
32048771 | Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation. | 2020 Jul |
6 |
| 17 |
32069373 | Recent advances in targeted small-molecule inhibitor therapy for non-small-cell lung cancer-An update. | 2020 Jun |
1 |
| 18 |
31558238 | Rapid Postoperative Relapse in ALK-Positive Locally Advanced NSCLC Patient with Complete Pathological Response to Neoadjuvant Crizotinib. | 2019 Oct |
1 |
| 19 |
31569004 | Discovery of 2-aminopyridines bearing a pyridone moiety as potent ALK inhibitors to overcome the crizotinib-resistant mutants. | 2019 Dec 1 |
2 |
| 20 |
31616158 | Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer. | 2019 |
1 |
| 21 |
31654622 | Cytotoxicity of curcumin derivatives in ALK positive non-small cell lung cancer. | 2019 Dec 15 |
2 |
| 22 |
31656659 | Real world experience on treatment, outcome and toxicity of crizotinib in patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer. | 2019 Sep |
4 |
| 23 |
31696059 | Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center. | 2019 |
3 |
| 24 |
31852910 | Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells. | 2019 Dec 18 |
1 |
| 25 |
31857951 | New generation anaplastic lymphoma kinase inhibitors. | 2019 Nov |
1 |
| 26 |
31933785 | A case report on epithelioid inflammatory myofibroblastic sarcoma in the abdominal cavity. | 2019 |
1 |